, the results point to a link between oral contraceptives and liver cancer, with risk increasing with duration of use Neuberger et al., 1986; Yu et al., 1991; Tavani et al., 1993) . There is also some evidence that the effect persists for over 10 years after cessation of use (Tavani et al., 1993 Table I ). Those that did look for any association between the pill and cholangiocarcinoma have been inconclusive WHO, 1989; Hsing et al., 1992 
Evidence is accumulating from case-control studies of an association between the use of oral contraceptives and hepatocellular carcinoma in countries where the incidence of hepatitis B is low. Table I summarises the ten such studies exploring this relationship that have been published over the last decade. With the exception of two studies (WHO, 1989; Kew et al., 1990) , the results point to a link between oral contraceptives and liver cancer, with risk increasing with duration of use Neuberger et al., 1986; Yu et al., 1991; Tavani et al., 1993) . There is also some evidence that the effect persists for over 10 years after cessation of use (Tavani et al., 1993) . In contrast to the other studies, the two which did not demonstrate any association with liver cancer were both in areas where hepatitis B is endemic. For example. in Kew et al.'s study of liver cancer in black South African women, 96% of patients were hepatitis B positive, compared with 62% of the controls (relative risk 13.5).
Internationally, variations in incidence of and mortality from primary liver cancer are difficult to interpret because of changes in classification and variations in diagnostic accuracy over time and in different parts of the world (Stuver and Trichopoulos, 1994) . The most important aetiological factor for liver cancer world-wide may well be hepatitis B (Trichopoulos, 1992) . However, in countries where the incidence of hepatitis B is low and liver cancer is correspondingly rare, it may be that use of the oral contraceptive pill is an important determinant of liver cancer mortality trends in women. Since the late 1960s, the contraceptive pill has been in widespread use in the United Kingdom, to the extent that over 80% of women born in the UK in the 1950s have had some experience of it Thorogood and Vessey, 1990 Table I ). Those that did look for any association between the pill and cholangiocarcinoma have been inconclusive WHO, 1989; Hsing et al., 1992 . Vessey, 1990) .
What rise in mortality would have been anticipated in England and Wales from the case-control studies? Pooling of the results of some of the published case-control studies suggests that the summary relative risk is 2.6 for liver cancer from ever use of the pill (Prentice. 1991). If 80% of women in the United Kingdom take the pill at some point in their lives (Villard-Mackintosh et a!.* 1989). then the rate in women aged 45-54 might have been expected to have gone up from 5 per million (rate in 1978-80) to 11 per million. This has not been observed. While it is inappropriate to attribute causality (or lack of it) from interpretation of secular trends. the absence of any observed effect of the contraceptive pill on mortality from liver cancer in England and Wales must raise a question mark over the association between the pill and liver cancer that has been noted in case-control studies. . In a much larger study of 166 000 women carried out in the United States, ten deaths from liver cancer had occurred by the 12th year of follow-up (Colditz. 1994) . Ever use of oral contraception was not found to be related to risk of liver cancer mortality (relative risk 0.43. confidence interval 0.08-2.42). It is not possible to draw any firm conclusions from these cohort studies because of the low number of deaths from liver cancer. Nevertheless, they do provide some circumstantial evidence to question the relationship between the contraceptive pill and liver cancer.
Conclusion
The association between the oral contraceptive pill and liver cancer that has been observed in several case-control studies has not been reflected in the mortality trends for liver cancer in women in England and Wales over the last decade. This finding casts some doubt on the importance of the contraceptive pill from a public health perspective as a risk factor for liver cancer.
